All Articles
Less than half of patients with cancer who have mental disorders or emotional distress are referred for appropriate care. This article tackles head-on how to deal with these issues as a patient. Read More ›
By Mu Lin
Based on current and evolving scientific evidence, the cancer prevention guidelines have been shifting from a nutrient-centric approach to a more holistic approach of diet that is characterized as dietary patterns. Read More ›
Cancer affects all races, ethnicities, sexual orientations, genders, and nationalities. Read More ›
By Mu Lin
Cervical cancer during pregnancy can be successfully managed with a multidisciplinary treatment team and an individualized treatment strategy that optimizes maternal treatment while considering fetal safety. Read More ›
While painting this beautifully realistic rendition of a Clam Shack in Cape Cod, Eddie Sutherland was able to step back, focus on his art, and forget his cancer concerns for a while. Read More ›
In October 2021, the FDA approved a second indication for Tecartus (brexucabtagene autoleucel), a novel, genetically modified CAR T-cell therapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More ›
In October 2021, the FDA approved Scemblix (asciminib) for patients with chronic-phase Ph-positive chronic myeloid leukemia (CML) or CML associated with T315I mutation. Scemblix is a new type of drug that may improve outcomes over other therapies for some patients with CML. Read More ›
In October 2021, the FDA approved the immunotherapy Keytruda (pembrolizumab), in combination with chemotherapy and with or without Avastin (bevacizumab), for patients with persistent, recurrent, or metastatic cervical cancer and PD-L1 expression. Read More ›
Oncology navigator Sharon Gentry, RN, MSN, explains the value of reaching out to your navigator. A large part of the navigator’s job is to answer questions related to patient care, from transportation and insurance coverage options to cultural concerns, and everything in between. Read More ›
In November 2021, the FDA approved a new indication for the immunotherapy Keytruda (pembrolizumab) for adjuvant treatment (after surgery) of patients with renal-cell carcinoma that is at intermediate-high or high risk for recurrence. Read More ›